Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure

European Journal of Heart Failure

Volumn 6, Issue 4, 2004, Pages 501-508

  Cleland, John G F ^a   Ghosh, Justin ^a   Freemantle, Nick ^b   Kaye, Gerry C ^a   Nasir, Mansoor ^a   Clark, Andrew L ^a   Coletta, Alison P ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CASINO; DINAMIT; INSPIRE; RIO LIPIDS and CRT in heart failure; SCD HeFT; STRATUS US; WATCH

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID RECEPTOR ANTAGONIST; CARDIOVASCULAR AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; LEVOSIMENDAN; RIMONABANT; SIMVASTATIN; SPIRONOLACTONE; UNCLASSIFIED DRUG; WARFARIN;

ACCURACY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOLOGY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; COLLEGE; DIZZINESS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERANCE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; META ANALYSIS; MORTALITY; NAUSEA; OBESITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYSTEMATIC REVIEW; TECHNIQUE; UPPER RESPIRATORY TRACT INFECTION;

ANTICOAGULANTS; CARDIOLOGY; CLINICAL TRIALS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE, CONGESTIVE; HUMANS; META-ANALYSIS; MYOCARDIAL INFARCTION; PACEMAKER, ARTIFICIAL; PIPERIDINES; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; UNITED STATES; WARFARIN;

EID: 2942556913     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2004.04.014     Document Type: Review

References (37)

1. Cleland J.G.F. Is aspirin 'The Weakest Link' in cardiovascular prophylaxis. The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis. 44:2002;275-292
2. Cleland J.G.F., Bulpitt C.J., Falk R.H., Findlay I.N., Oakley C.M., Murray G., et al. Is aspirin safe for patients with heart failure? Br Heart J. 74:(3):1995;215-219
3. Cleland JGF, Findlay I, Jafri S, et al. The warfarin/aspirin study in heart failure (WASH): a randomised trial comparing anti-thrombotic strategies for patients with heart failure. Am Heart J 2004, In press
4. The WASH study steering committee and investigators. The WASH study (warfarin/aspirin study in heart failure): rationale, design and methods. Eur J Heart Fail. 1:1999;95-99
5. Massie BM, Krol WF, Ammon SE, et al. The warfarin and antiplatelet therapy in heart failure trial (WATCH): rationale, design and baseline patient characteristics. J Card Fail 2004, 10:101-102
6. Moss A.H.J., Hall W.J., Cannom D.S., et al. Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 335:1996;1933-1940
7. Moss A.H.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 346:2002;877-883
8. Bigger J.T.J. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary artery bypass graft surgery. N Engl J Med. 337:1997;1569-1575. for the CABG-Patch trial investigators
9. Cleland J.G.F., Freemantle N., Kaye G., et al. Clinical trials update from the American Heart Association meeting: Ω-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplant study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Fail. 6:2004;109-115
10. Cleland J.G.F., Coletta A.P., Nikitin N., Louis A., Clark A. Update of clinical trials from the American College of Cardiology EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans. Eur J Heart Fail. 5:2003;391-398
11. Klein H., Auricchio A., Reek S., Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HeFT and MADIT-II. Am J Cardiol. 83:1999;91D-97D
12. The DAVID trial investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator. J Am Med Assoc. 288:2002;3115-3123
13. Cleland J.G.F., Ghosh J., Khan N.K., Ghio S., Tavazzi L., Kaye G. Multi-chamber pacing: a perfect solution for cardiac mechanical dyssynchrony? Eur Heart J. 24:2003;384-390
14. Cleland J.G.F., Kappenberger L.J., Tavazzi L., Klein W., Erdmann E. Design and methodology of the CARE-HF trial. A randomised trial of cardiac resynchronisation in patients with heart failure and ventricular dyssynchrony. Eur J Heart Fail. 3:2001;481-489
15. Cleland J.G.F., Freemantle N., Ball S.G., et al. The heart failure revascularization trial (HEART): rationale, design and methodology. Eur J Heart Fail. 5:2003;295-303
16. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk of ventricular arrhythmias. N Engl J Med. 335:1996;1933-1940
17. Buxton A.E., Lee K.L., Fisher J.D., et al. A randomised study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 341:1999;1882-1890. for the multicentre unsustained tachycardia trial investigators
18. Hohnloser S.H., Connolly S.J., Kuck K.H., et al. The defibrillator in acute myocardial infarction trial (DINAMIT): study protocol. Am Heart J. 140:2000;735-739. for the DINAMIT investigators
19. Follath F., Cleland J.G.F., Just H., et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study); a randomised double-blind trial. Lancet. 360:2002;196-202
20. Thackray S., Eastaugh J., Freemantle N., Cleland J.G. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure - a meta regression analysis. Eur J Heart Fail. 4:2002;515-529
21. Moiseyev V.S., Poder P., Andrejevs N., et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 18:2002;1422-1432
22. Packer M., Colucci W.S., Fisher L., et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study. J Card Fail. 9:2003;S61. Abstract
23. Task force for the diagnosis and treatment of chronic heart failure, ESC: Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22: pp. 1527-1560
24. Dakik HA, Filipchuk NG, Pratt CM, et al. for the INSPIRE investigators. Suppression of post-infarction myocardial ischemia with medical and revascularisation therapies: results from the adenosine sestamibi post-infarction evaluation (INSPIRE) trial. Circulation 2003; 108: abstract 2888
25. Davos C.H., Doehner W., Rauchhaus M., et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail. 9:2003;29-35
26. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 346:(24):2002;1845-1853
27. Ghosh J., DeSilva R., Kaye G.C., et al. The predictive value of QRS duration as a marker of ventricular dyssynchrony. J Am Coll Cardiol. 43:(5 supp A):2004;131A. Abstract
28. Bleeker G.B., Schalij M.J., Molhoek S.G., et al. Relationship between QRS duration and left ventricular dyssynchrony in patients with end stage heart failure. J Am Coll Cardiol. 43:(5 Supp A):2004;146A. Abstract
29. Yu C.M., Lin H., Zhang Q., Sanderson J.E. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart. 89:(1):2003;54-60
30. Kanzaki H., Raveen B., Severyn D.A., et al. Echocardiographic tissue synchronization imaging predicts acute response to biventricular pacing therapy. J Am Coll Cardiol. 43:(5 Supp A):2004;333A. Abstract
31. Kanzaki H., Bazaz R., Dohi K., Gorcsan J., Schwartzman D. Mechanical activation mapping with strain imaging: a new approach to localize ventricular lead placement after cardiac resynchronization therapy. J Am Coll Cardiol. 43:(5 Supp A):2004;153A. Abstract
32. Desai A.D., Mor-Avi V., Sugeng L., et al. Use of real-time three-dimensional echocardiography to measure ventricular dyssynchrony and assess cardiac resynchronization in heart failure patients. J Am Coll Cardiol. 43:(5 Supp A):2004;309A. Abstract
33. Kapetanakis S., Cooklin M., Williams I.L., Kearney M., Monaghan M.J. 3D echocardiographic quantification of left ventricular asynchrony in patients selected for cardiac resynchronization therapy. J Am Coll Cardiol. 43:(5 Supp A):2004;309A. Abstract
34. Kocovic D., Ross H., Lynn T., Laidlaw D. Lead position and long-term survival with biventricular pacing. J Am Coll Cardiol. 43:(5 Supp A):2004;148A. Abstract
35. Burkhardt JD, Khaykin Y, Joseph G, et al. Narrowing of the widest QRS predicts improvement in functional class and echocardiographic parameters in patients with cardiac resynchronisation therapy devices. J Am Coll Cardiol 2004; 43 (5 Suppl. A): 131 A (Abstract)
36. Ng K., Starling R., Kedia N., et al. Benefit of biventricular pacing in subsets of patients with heart failure. J Am Coll Cardiol. 43:(5 Supp A):2004;237A. Abstract
37. Pamboukian S.V., Nisar I., Patel S., et al. Upgrade from standard right sided pacing to cardiac resynchronization therapy shows clinical benefit as in de novo implantation. J Am Coll Cardiol. 43:(5 Supp A):2004;237A. Abstract